News Sanofi scores in MS with CD40 antibody frexalimab Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.